XOMA Royalty Corp files 10-Q

XOMA Royalty Corporation reported a net income of $4.5 million for the first quarter of 2026, a significant increase from $2.4 million in the prior year period, driven by higher income from purchased receivables under the EIR method and gains on acquisitions. The company also announced a definitive agreement to be acquired by Ligand Pharmaceuticals for approximately $739 million in cash plus a contingent value right.